Abstract
OBJECTIVE: Cancer cell reprogramming is a potential tool to study cancer progression, disease pathology, and drug sensitivity. Prior to performing cancer reprogramming studies, it is important to evaluate the stemness predisposition of cells that will be reprogrammed. We performed a proof-of-concept study with chronic myeloid leukemia K562 cells in order to evaluate their tendency for cancer cell reprogramming. MATERIALS AND METHODS: Expression of reprogramming factors, pluripotency markers, and tumor-suppressor genes was analyzed at gene and protein levels via real-time reverse transcription-polymerase chain reaction and flow cytometry. Human peripheral blood mononuclear cells (PBMCs) were used as a positive control. RESULTS: K562 cells were shown to express higher levels of most of the reprogramming factors and pluripotency markers. Expression of p53, which is one of the main regulators during the generation of induced pluripotent stem cells, was found to be lower in K562 cells compared to PBMCs, whereas the other tumor-suppressor genes showed higher expression levels. CONCLUSION: This study suggested that, similar to healthy human PBMCs, K526 cells could be used in cancer cell reprogramming studies. Generating induced pluripotent stem cells from leukemia cells could help scientists to establish chronic myeloid leukemia models in vitro for a better understanding of therapy resistance and development of novel therapeutic targets.